We compared HIV antibody results between two of three treatment groups of the Children with HIV Early Antiretroviral Therapy ( CHER ) trial , done from July , 2005 , until July , 2011 , in which infants with HIV infection aged 57-120 weeks with a percentage of CD4-positive T lymphocytes of at least 25 % were randomly assigned to immediate ART for 96 weeks ( ART-96W ) or deferred ART until clinical or immunological progression ( ART-Def ) .